Brief: Bylvay (Odevixibat) Approved In Japan For Rare Liver Disease Pfic
19/09/2025 13:00
Sept 19 (Reuters) - Ipsen SA IPN.PA: BYLVAY (ODEVIXIBAT) APPROVED IN JAPAN FOR RARE LIVER DISEASE PFIC Source text: ID:nGNEp6Sj0 Further company coverage: IPN.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients